Pitarokoili, Kalliopi
Gold, Ralf
Article History
First Online: 17 November 2017
Competing interests
: K.P. received speaker honoraria and travel funding from Bayer Schering Pharma, Biogen Idec and Novartis. R.G. serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Novartis and Teva Pharmaceutical Industries Ltd; has received speaker honoraria from Bayer Schering Pharma, Biogen Idec, Novartis and Teva Pharmaceutical Industries Ltd; serves as editor for Therapeutic Advances in Neurological Disorders and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis and Teva Pharmaceutical Industries Ltd, none related to this manuscript.